Figure 4.

Activation of p53 and its transcriptional functions are defective in PELP1-depleted cells. (a) ZR75 cells stably expressing PELP1-shRNA or the control shRNA vector were treated with 1 μM camptothecin and at different time periods, cell lysates were prepared and subjected to western blotting with indicated antibodies. (b) ZR75 cells stably expressing PELP1-shRNA or control shRNA vector were treated with either cisplatin (25 μM for 18 h), camptothecin (10 μM for 12h) or etoposide (50 μM for 12 h). RNA was isolated and the status of p53 target genes was analyzed by qRT-PCR analysis. *P<0.05; **P<0.01; ***P<0.001. (c) ZR75 cells stably expressing PELP1-shRNA or the control shRNA vector were treated with either 50 μM etoposide for 12 h, or γ-radiation (5 Gy). The status of p53 target genes was analyzed by western blotting of total lysates